Iceland· IS-EU/1/24/1837/001
Adzynma
A apadamtase alfa und cinaxadamtase alfa product containing apadamtase alfa,radamts13, registered in Iceland by Takeda Manufacturing Austria AG. The same ATC class is registered in 10 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Apadamtase alfa und cinaxadamtase alfa is registered in 10 of 19 countries.
Countries holding a registration under ATC B01AD13 (apadamtase alfa und cinaxadamtase alfa), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Apadamtase alfa und cinaxadamtase alfa · ATC B01AD13
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Apadamtase alfa,rADAMTS13
- Manufacturer
- Takeda Manufacturing Austria AG
- Country
- Iceland (IS)
- ATC code
- B01AD13
- ATC class
- Apadamtase alfa und Cinaxadamtase alfa
- Defined daily dose
- 200 E, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B01AD13
Apadamtase alfa und cinaxadamtase alfa, as other registers publish it.
- PolandAdzynmaTakeda Manufacturing Austria AG
- PolandAdzynmaTakeda Manufacturing Austria AG
- NorwayAdzynmaTakeda Manufacturing Austria AG
- IcelandAdzynmaTakeda Manufacturing Austria AG
- NorwayAdzynmaTakeda Manufacturing Austria AG
- DenmarkADZYNMATakeda Manufacturing Austria AG
- CzechiaADZYNMATakeda Manufacturing Austria AG, Vídeň
- FinlandADZYNMATakeda Manufacturing Austria AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ccfb90b6-774d-4965-a72f-d3885e559ca4 GET /v1/drugs/ccfb90b6-774d-4965-a72f-d3885e559ca4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyfsstofn og leysir, lausn",
"source": "lyfjastofnun",
"atc_raw": "B01AD13",
"marketed": false,
"strength": "500 a.e.",
"ma_number": "EU/1/24/1837/001",
"substance": "Apadamtase alfa,rADAMTS13",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45505"
}See everything about apadamtase alfa und cinaxadamtase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.